To the Editor: We would like to comment on
several points raised by Dr Sacks in his Editorial1
accompanying our report of the MIRACL study.2
The findings of the MIRACL study demonstrated that short-term, intensive lipid-lowering
therapy reduces recurrent ischemic cardiovascular events in patients after
ACS. We chose 80 mg/d of atorvastatin, the highest approved dosage with the
greatest lipid-lowering effects, to maximize the likelihood of observing a
benefit of treatment. We agree with Sacks that it remains to be determined
if a lower dose of atorvastatin and/or other statins would have similar effects.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.